<DOC>
	<DOCNO>NCT01051258</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy AeriSeal treatment patient advance emphysema .</brief_summary>
	<brief_title>AeriSeal System Lung Volume Reduction</brief_title>
	<detailed_description>The purpose study evaluate safety efficacy AeriSeal treatment patient advance homogeneous heterogeneous emphysema .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Patients must diagnosis advanced emphysema define FEV1/FVC &lt; 70 % predict , FEV1 &lt; 50 % predict , TLC &gt; 100 % predict , RV &gt; 135 % predict . Patients must persistent symptom despite medical therapy either candidate Lung Volume Reduction Surgery ( LVRS ) elect undergo LVRS . Patients must &gt; 40 year age , symptom despite medical therapy , none prespecified comorbid condition could influence study outcome ability tolerate bronchoscopy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Polymeric Lung Volume Reduction ( PLVR )</keyword>
	<keyword>Biologic Lung Volume Reduction ( BLVR )</keyword>
	<keyword>AeriSeal</keyword>
	<keyword>treatment</keyword>
	<keyword>device</keyword>
	<keyword>breathing</keyword>
	<keyword>COPD</keyword>
	<keyword>emphysema</keyword>
	<keyword>heterogeneous</keyword>
	<keyword>homogeneous</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Pulmonary Disease , Chronic Obstructive</keyword>
</DOC>